|
AU2016256668A1
|
|
Prevention and treatment of amyloidogenic disease
|
|
JP2014001232A
|
|
Treatment of amyloidogenic disease
|
|
AU2013209361A1
|
|
Immunotherapy regimes dependent on ApoE status
|
|
BR112014033066A2
|
|
method for treating a patient diagnosed with alzheimer's disease, humanized, chimeric or antibody coated form, and, antibody.
|
|
AU2013206069A1
|
|
Prevention and treatment of amyloidogenic disease
|
|
CA2867338A1
|
|
Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease
|
|
JP2012233002A
|
|
Amyloid beta antibody for use in improving cognition
|
|
AU2011265382A1
|
|
Prevention and treatment of amyloidogenic disease
|
|
JP2012034697A
|
|
HUMANIZED ANTIBODY RECOGNIZING β-AMYLOID PEPTIDE
|
|
JP2012050437A
|
|
Humanized antibody recognizing beta amyloid peptide
|
|
WO2011133919A1
|
|
Use of tau to monitor immunotherapy
|
|
BRPI0823507A2
|
|
Uses of an antibody specifically connecting to an open n terminal epit and a apoe4 copy number measurement
|
|
NZ622460A
|
|
Immunotherapy regimes dependent on apoe status
|
|
JO3076B1
|
|
Immunotherapy regimes dependent on apoe status
|
|
AU2008203784A1
|
|
Prevention and treatment of amyloidogenic disease
|
|
US2009142270A1
|
|
Treatment of cerebral amyloid angiopathy
|
|
AU2008242648A1
|
|
Prevention and treatment of cerebral amyloid angiopathy
|
|
US2008221306A1
|
|
Humanized antibodies that recognize beta amyloid peptide
|
|
US2007238154A1
|
|
Humanized antibodies that recognize β-amyloid peptide
|
|
US2007154480A1
|
|
Humanized antibodies that recognize beta amyloid peptide
|
